Home / Articles / Progress in the medical chemistry of organoboron compounds

Progress in the medical chemistry of organoboron compounds

Anna Nikolaevna Tevyashova 1
Anna Nikolaevna Tevyashova
, 
Mikhail Vasil'evich Chudinov 2
Mikhail Vasil'evich Chudinov
1 G. F. Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow
2 MIREA — Russian Technological University, Moscow
10.1070/RCR4977
Published 30 November 2020
Review , RCR4977, Volume 90, Issue 4, 451-487
32
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Tevyashova A. N., Chudinov M. V. Progress in the medical chemistry of organoboron compounds // Russian Chemical Reviews. 2020. Vol. 90. No. 4. pp. 451-487.
GOST all authors (up to 50)
Copy cite
Tevyashova A. N., Chudinov M. V. Progress in the medical chemistry of organoboron compounds // Russian Chemical Reviews. 2020. Vol. 90. No. 4. pp. 451-487.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RCR4977
UR - https://rcr.colab.ws/publications/10.1070/RCR4977
TI - Progress in the medical chemistry of organoboron compounds
T2 - Russian Chemical Reviews
AU - Tevyashova, Anna Nikolaevna
AU - Chudinov, Mikhail Vasil'evich
PY - 2020
DA - 2020/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 451-487
IS - 4
VL - 90
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2020_Tevyashova,
author = {Anna Nikolaevna Tevyashova and Mikhail Vasil'evich Chudinov},
title = {Progress in the medical chemistry of organoboron compounds},
journal = {Russian Chemical Reviews},
year = {2020},
volume = {90},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RCR4977},
number = {4},
pages = {451--487},
doi = {10.1070/RCR4977}
}
MLA
Cite this
MLA
Copy cite
Tevyashova, Anna Nikolaevna, and Mikhail Vasil'evich Chudinov. “Progress in the medical chemistry of organoboron compounds.” Russian Chemical Reviews, vol. 90, no. 4, Nov. 2020, pp. 451-487. https://rcr.colab.ws/publications/10.1070/RCR4977.
Views / Visits / Downloads
28 / 27 / 3

Keywords

benzodiazaborines
benzoxaborines
benzoxaboroles
biological activity
boron clusters
boron neutron capture therapy
boronic acids
borylation
carboranes
drug delivery systems
drug design

Abstract

The review aims to draw attention to the latest advances in the organoboron chemistry and therapeutic use of organoboron compounds. The synthetic strategies towards boron-containing compounds with proven \emph{in vitro} and/or \emph{in vivo} biological activities, including derivatives of boronic acids, benzoxaboroles, benzoxaborines and benzodiazaborines, are summarized. Approaches to the synthesis of hybrid structures containing an organoboron moiety as one of the pharmacophores are considered, and the effect of this modification on the pharmacological activity of the initial molecules is analyzed. On the basis of analysis of the published data, the most promising areas of research in the field of organoboron compounds are identified, including the latest methods of synthesis, modification and design of effective therapeutic agents.

The bibliography includes 246 references.

References

1.
Element 5 – Boron
Rendina L.M.
Australian Journal of Chemistry , 2019
2.
Boron Chemistry for Medical Applications
Ali F., S Hosmane N., Zhu Y.
Molecules , 2020
3.
Boron in drug design: Recent advances in the development of new therapeutic agents
Fernandes G.F., Denny W.A., Dos Santos J.L.
European Journal of Medicinal Chemistry , 2019
4.
Synthesis of biologically active boron-containing compounds
Yang F., Zhu M., Zhang J., Zhou H.
MedChemComm , 2018
5.
Will morphing boron-based inhibitors beat the β-lactamases?
Krajnc A., Lang P.A., Panduwawala T.D., Brem J., Schofield C.J.
Current Opinion in Chemical Biology , 2019
6.
Boron agents for neutron capture therapy
Hu K., Yang Z., Zhang L., Xie L., Wang L., Xu H., Josephson L., Liang S.H., Zhang M.
Coordination Chemistry Reviews , 2020
7.
rcr_90_4_451bib7
Sivaev
2009
8.
Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018)
Nocentini A., Supuran C.T., Winum J.
Expert Opinion on Therapeutic Patents , 2018
9.
Metallomimetic Chemistry of Boron
Légaré M., Pranckevicius C., Braunschweig H.
Chemical Reviews , 2019
10.
Ring Structure and Aromatic Substituent Effects on the pKa of the Benzoxaborole Pharmacophore
Tomsho J.W., Pal A., Hall D.G., Benkovic S.J.
ACS Medicinal Chemistry Letters , 2011
11.
Characterization of the Dynamic Equilibrium between Closed and Open Forms of the Benzoxaborole Pharmacophore
Vshyvenko S., Clapson M.L., Suzuki I., Hall D.G.
ACS Medicinal Chemistry Letters , 2016
13.
rcr_90_4_451bib13
Sivaev
Ros. Khim. Zh. , 2004
15.
Proteasome Inhibitor Drugs
Fricker L.D.
Annual Review of Pharmacology and Toxicology , 2020
17.
Ni/Cu-Catalyzed Defluoroborylation of Fluoroarenes for Diverse C–F Bond Functionalizations
Niwa T., Ochiai H., Watanabe Y., Hosoya T.
Journal of the American Chemical Society , 2015
18.
Photocatalytic C–F Bond Borylation of Polyfluoroarenes with NHC-boranes
Xia P., Ye Z., Hu Y., Xiao J., Chen K., Xiang H., Chen X., Yang H.
Organic Letters , 2020
19.
rcr_90_4_451bib19
Tian
J. Am. Chem. Soc. , 2018
21.
Ipso-Borylation of Aryl Ethers via Ni-Catalyzed C–OMe Cleavage
Zarate C., Manzano R., Martin R.
Journal of the American Chemical Society , 2015
22.
Visible Light-Induced Borylation of C–O, C–N, and C–X Bonds
Jin S., Dang H.T., Haug G.C., He R., Nguyen V.D., Nguyen V.T., Arman H.D., Schanze K.S., Larionov O.V.
Journal of the American Chemical Society , 2020
23.
Combined Theoretical and Experimental Studies of Nickel-Catalyzed Cross-Coupling of Methoxyarenes with Arylboronic Esters via C–O Bond Cleavage
Schwarzer M.C., Konno R., Hojo T., Ohtsuki A., Nakamura K., Yasutome A., Takahashi H., Shimasaki T., Tobisu M., Chatani N., Mori S.
Journal of the American Chemical Society , 2017
24.
Palladium-Catalyzed Borylation of Aryl Sulfoniums with Diborons
Minami H., Otsuka S., Nogi K., Yorimitsu H.
ACS Catalysis , 2017
28.
Origin of the Difference in Reactivity between Ir Catalysts for the Borylation of C-H Bonds.
Oeschger R.J., Larsen M.A., Bismuto A., Hartwig J.F.
Journal of the American Chemical Society , 2019
29.
rcr_90_4_451bib29
Yamamoto
J. Am. Chem. Soc. , 2012
30.
Metal-free catalytic C-H bond activation and borylation of heteroarenes
Légaré M., Courtemanche M., Rochette É., Fontaine F.
Science , 2015
31.
Mechanism and Scope of Nickel-Catalyzed Decarbonylative Borylation of Carboxylic Acid Fluorides
Malapit C.A., Bour J.R., Laursen S.R., Sanford M.S.
Journal of the American Chemical Society , 2019
33.
Palladium-Catalyzed Borylation of Primary Alkyl Bromides
Joshi-Pangu A., Ma X., Diane M., Iqbal S., Kribs R.J., Huang R., Wang C., Biscoe M.R.
Journal of Organic Chemistry , 2012
34.
Cobalt(I)-Catalyzed Borylation of Unactivated Alkyl Bromides and Chlorides
Verma P.K., Prasad K.S., Varghese D., Geetharani K.
Organic Letters , 2020
35.
Manganese-Catalyzed Borylation of Unactivated Alkyl Chlorides
Atack T.C., Cook S.P.
Journal of the American Chemical Society , 2016
36.
Highly Efficient Synthesis of Alkylboronate Esters via Cu(II)-Catalyzed Borylation of Unactivated Alkyl Bromides and Chlorides in Air
Bose S.K., Brand S., Omoregie H.O., Haehnel M., Maier J., Bringmann G., Marder T.B.
ACS Catalysis , 2016
37.
Transition-Metal-Free Borylation of Alkyl Iodides via a Radical Mechanism
Liu Q., Hong J., Sun B., Bai G., Li F., Liu G., Yang Y., Mo F.
Organic Letters , 2019
38.
Photochemical Organocatalytic Borylation of Alkyl Chlorides, Bromides, and Sulfonates
Mazzarella D., Magagnano G., Schweitzer-Chaput B., Melchiorre P.
ACS Catalysis , 2019
39.
Decarboxylative Borylation of mCPBA-Activated Aliphatic Acids
Wei D., Liu T., Zhou B., Han B.
Organic Letters , 2019
40.
Synthesis of aminoboronic acid derivatives: an update on recent advances
Šterman A., Sosič I., Gobec S., Časar Z.
Organic Chemistry Frontiers , 2019
42.
Silica‐Supported Tripod Triarylphosphane: Application to Transition Metal‐Catalyzed C( sp 3 )H Borylations
Iwai T., Murakami R., Harada T., Kawamorita S., Sawamura M.
Advanced Synthesis and Catalysis , 2014
43.
Rh-Catalyzed Borylation of N-Adjacent C(sp3)–H Bonds with a Silica-Supported Triarylphosphine Ligand
Kawamorita S., Miyazaki T., Iwai T., Ohmiya H., Sawamura M.
Journal of the American Chemical Society , 2012
44.
α-Amidoboronate esters by amide-directed alkane C H borylation
Hyland S.N., Meck E.A., Tortosa M., Clark T.B.
Tetrahedron Letters , 2019
46.
rcr_90_4_451bib46
Bai
J. Am. Chem. Soc. , 2019
47.
Asymmetric Hydrogenation of α-Boryl Enamides Enabled by Nonbonding Interactions
Fan D., Zhang J., Hu Y., Zhang Z., Gridnev I.D., Zhang W.
ACS Catalysis , 2020
49.
Asymmetric Synthesis of α-Aminoboronates via Rhodium-Catalyzed Enantioselective C(sp3)–H Borylation
Reyes R.L., Sato M., Iwai T., Sawamura M.
Journal of the American Chemical Society , 2019
50.
rcr_90_4_451bib50
Schwamb
J. Am. Chem. Soc. , 2018
51.
Structural and Biological Overview of Boron-containing Amino Acids in the Medicinal Chemistry Field
García A.A., Rayevsky A., Andrade-Jorge E., Trujillo-Ferrara J.G.
Current Medicinal Chemistry , 2018
52.
Effects of boron-containing compounds on immune responses: review and patenting trends
Romero-Aguilar K.S., Arciniega-Martínez I.M., Farfán-García E.D., Campos-Rodríguez R., Reséndiz-Albor A.A., Soriano-Ursúa M.A.
Expert Opinion on Therapeutic Patents , 2019
53.
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang H., Chen X., Li K., Cheaito H., Yang Q., Wu G., Liu J., Dou Q.P.
Seminars in Cancer Biology , 2021
54.
Utility of boron in dermatology
Jackson D.G., Cardwell L.A., Oussedik E., Feldman S.R.
Journal of Dermatological Treatment , 2019
57.
Ixazomib – the first oral proteasome inhibitor
Xie J., Wan N., Liang Z., Zhang T., Jiang J.
Leukemia and Lymphoma , 2019
58.
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Gupta N., Hanley M.J., Xia C., Labotka R., Harvey R.D., Venkatakrishnan K.
Clinical Pharmacokinetics , 2018
59.
Clinical and Marketed Proteasome Inhibitors for Cancer Treatment
Zhang J., Wu P., Hu Y.
Current Medicinal Chemistry , 2013
60.
Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
Scarpino, Bajusz, Proj, Gobec, Sosič, Gobec, Ferenczy, Keserű
Molecules , 2019
61.
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome
Zhang X., Adwal A., Turner A.G., Callen D.F., Abell A.D.
ACS Medicinal Chemistry Letters , 2016
62.
Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer
Lei M., Feng H., Bai E., Zhou H., Wang J., Qin Y., Zhang H., Wang X., Liu Z., Hai O., Liu J., Zhu Y.
Organic and Biomolecular Chemistry , 2019
63.
Novel p-Functionalized Chromen-4-on-3-yl Chalcones Bearing Astonishing Boronic Acid Moiety as MDM2 Inhibitor: Synthesis, Cytotoxic Evaluation and Simulation Studies
Bhatia R.K., Singh L., Garg R., Kaur M., Yadav M., Madan J., Kancherla S., Pissurlenkar R.R., Coutinho E.C.
Medicinal Chemistry , 2019
64.
Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design
Katsamakas S., Papadopoulos A., Hadjipavlou-Litina D.
Molecules , 2016
65.
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis
Cohen O.C., Sharpley F., Gillmore J.D., Lachmann H.J., Sachchithanantham S., Mahmood S., Fontana M., Whelan C.J., Martinez‐Naharro A., Kyriakou C., Rabin N., Popat R., Yong K., Cheesman S., Shah R., et. al.
British Journal of Haematology , 2020
66.
Combinatorial ixazomib and belinostat therapy induces NFE2L2‐dependent apoptosis in Hodgkin and T‐cell lymphoma
Passero F.C., Ravi D., McDonald J.T., Beheshti A., David K.A., Evens A.M.
British Journal of Haematology , 2019
68.
New insights into the roles of CHOP-induced apoptosis in ER stress
Li Y., Guo Y., Tang J., Jiang J., Chen Z.
Acta Biochimica et Biophysica Sinica , 2014
71.
Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors
Ge Y., Li A., Wu J., Feng H., Wang L., Liu H., Xu Y., Xu Q., Zhao L., Li Y.
European Journal of Medicinal Chemistry , 2017
72.
Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors
Zhang W., Bai H., Han L., Zhang H., Xu B., Cui J., Wang X., Ge Z., Li R.
Bioorganic and Medicinal Chemistry Letters , 2018
73.
rcr_90_4_451bib73
Wan
Int. J. Mol. Med. , 2010
74.
Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer
Li X., Wu S., Dong G., Chen S., Ma Z., Liu D., Sheng C.
ACS Medicinal Chemistry Letters , 2020
75.
Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents
Wang S., Fang K., Dong G., Chen S., Liu N., Miao Z., Yao J., Li J., Zhang W., Sheng C.
Journal of Medicinal Chemistry , 2015
76.
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs
González-Bello C., Rodríguez D., Pernas M., Rodríguez Á., Colchón E.
Journal of Medicinal Chemistry , 2019
77.
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Hecker S.J., Reddy K.R., Totrov M., Hirst G.C., Lomovskaya O., Griffith D.C., King P., Tsivkovski R., Sun D., Sabet M., Tarazi Z., Clifton M.C., Atkins K., Raymond A., Potts K.T., et. al.
Journal of Medicinal Chemistry , 2015
78.
Structure-Based Design Guides the Improved Efficacy of Deacylation Transition State Analogue Inhibitors of TEM-1 β-Lactamase,
Ness S., Martin R., Kindler A.M., Paetzel M., Gold M., Jensen S.E., Jones J.B., Strynadka N.C.
Biochemistry , 2000
79.
Stereoselective synthesis of the indolizidine core of the allopumiliotoxins
Tan C., Stork T., Feeder N., Holmes A.B.
Tetrahedron Letters , 1999
80.
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
Lomovskaya O., Sun D., Rubio-Aparicio D., Nelson K., Tsivkovski R., Griffith D.C., Dudley M.N.
Antimicrobial Agents and Chemotherapy , 2017
81.
Studies on the inhibition of AmpC and other β-lactamases by cyclic boronates
Cahill S.T., Tyrrell J.M., Navratilova I.H., Calvopiña K., Robinson S.W., Lohans C.T., McDonough M.A., Cain R., Fishwick C.W., Avison M.B., Walsh T.R., Schofield C.J., Brem J.
Biochimica et Biophysica Acta - General Subjects , 2019
84.
Structure-Based Development of (1-(3'-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-β-Lactamases.
Wang Y., Liu S., Yu Z., Lei Y., Huang M., Yan Y., Ma Q., Zheng Y., Deng H., Sun Y., Wu C., Yu Y., Chen Q., Wang Z., Wu Y., et. al.
Journal of Medicinal Chemistry , 2019
85.
Leveraging Peptide Substrate Libraries to Design Inhibitors of Bacterial Lon Protease
Babin B.M., Kasperkiewicz P., Janiszewski T., Yoo E., Dra̧g M., Bogyo M.
ACS Chemical Biology , 2019
86.
Branched Peptides: Acridine and Boronic Acid Derivatives as Antimicrobial Agents
Wynn J.E., Zhang W., Falkinham J.O., Santos W.L.
ACS Medicinal Chemistry Letters , 2017
87.
Preliminary investigations into the synthesis and antimicrobial activities of boron-containing capsaicinoids
Ramsaywack S., Bos A., Vogels C.M., Gray C.A., Westcott S.A.
Canadian Journal of Chemistry , 2018
88.
Turning Fear of Boron Toxicity into Boron-containing Drug Design
Soriano-Ursúa M.A., Farfán-García E.D., Geninatti-Crich S.
Current Medicinal Chemistry , 2019
89.
Antifungal activity and tautomeric cyclization equilibria of formylphenylboronic acids
Borys K.M., Wieczorek D., Pecura K., Lipok J., Adamczyk-Woźniak A.
Bioorganic Chemistry , 2019
91.
The P2X7 Receptor in Infection and Inflammation
Di Virgilio F., Dal Ben D., Sarti A.C., Giuliani A.L., Falzoni S.
Immunity , 2017
92.
Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response
Faria R.X., de Jesus Hiller N., Salles J.P., Resende J.A., Diogo R.T., von Ranke N.L., Bello M.L., Rodrigues C.R., Castro H.C., de Luna Martins D.
Journal of Bioenergetics and Biomembranes , 2019
93.
Cell-based assays and molecular dynamics analysis of a boron-containing agonist with different profiles of binding to human and guinea pig beta2 adrenoceptors
Soriano-Ursúa M.A., Bello M., Hernández-Martínez C.F., Santillán-Torres I., Guerrero-Ramírez R., Correa-Basurto J., Arias-Montaño J., Trujillo-Ferrara J.G.
European Biophysics Journal , 2018
94.
rcr_90_4_451bib94
Torssell
Ark. Kemi , 1957
96.
Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis
Baker S.J., Zhang Y., Akama T., Lau A., Zhou H., Hernandez V., Mao W., Alley M.R., Sanders V., Plattner J.J.
Journal of Medicinal Chemistry , 2006
97.
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
Jacobs R.T., Nare B., Wring S.A., Orr M.D., Chen D., Sligar J.M., Jenks M.X., Noe R.A., Bowling T.S., Mercer L.T., Rewerts C., Gaukel E., Owens J., Parham R., Randolph R., et. al.
PLoS Neglected Tropical Diseases , 2011
99.
Benzoxaboroles – Old compounds with new applications
Adamczyk-Woźniak A., Cyrański M.K., Żubrowska A., Sporzyński A.
Journal of Organometallic Chemistry , 2009
100.
Recent Developments in the Chemistry and Biological Applications of Benzoxaboroles
Adamczyk-Woźniak A., Borys K.M., Sporzyński A.
Chemical Reviews , 2015
102.
Benzoboroxoles: Synthesis and applications in medicinal chemistry
Mereddy G.R., Chakradhar A., Rutkoski R.M., Jonnalagadda S.C.
Journal of Organometallic Chemistry , 2018
103.
The synthesis of benzoxaboroles and their applications in medicinal chemistry
Zhang J., Zhu M., Lin Y., Zhou H.
Science China Chemistry , 2013
104.
rcr_90_4_451bib104
Fuscaldo
2019
105.
rcr_90_4_451bib105
Zhu
Org. Biomol. Chem. , 2015
106.
A convenient one-pot synthesis of boroxoles from diboronic acid
Lafitte G., Kunihiro K., Bonneaud C., Dréan B., Gaigne F., Parnet V., Pierre R., Raffin C., Vatinel R., Fournier J., Musicki B., Ouvry G., Bouix-Peter C., Tomas L., Harris C.S., et. al.
Tetrahedron Letters , 2017
107.
An Efficient Benzoxaborole One‐Pot Synthesis by Silia Cat DPP‐Pd Heterogeneous Catalysis using Diboronic Acid
Kunihiro K., Dumais L., Lafitte G., Varvier E., Tomas L., Harris C.S.
Advanced Synthesis and Catalysis , 2018
109.
rcr_90_4_451bib109
Vanveller
RSC Adv. , 2013
110.
Protection of the Benzoxaborole Moiety: Synthesis and Functionalization of Zwitterionic Benzoxaborole Complexes
Gamrat J.M., Mancini G., Burke S.J., Colandrea R.C., Sadowski N.R., Figula B.C., Tomsho J.W.
Journal of Organic Chemistry , 2018
111.
New conjugates of polyene macrolide amphotericin B with benzoxaboroles: Synthesis and properties
Tevyashova A.N., Korolev A.M., Trenin A.S., Dezhenkova L.G., Shtil A.A., Polshakov V.I., Savelyev O.Y., Olsufyeva E.N.
Journal of Antibiotics , 2016
112.
Synthesis and structural elucidation of novel antifungal N-(fluorophenyl)piperazinyl benzoxaboroles and their analogues
Borys K.M., Matuszewska A., Wieczorek D., Kopczyńska K., Lipok J., Madura I.D., Adamczyk-Woźniak A.
Journal of Molecular Structure , 2019
113.
The influence of fluorine position on the properties of fluorobenzoxaboroles
Adamczyk-Woźniak A., Cabaj M.K., Dominiak P.M., Gajowiec P., Gierczyk B., Lipok J., Popenda Ł., Schroeder G., Tomecka E., Urbański P., Wieczorek D., Sporzyński A.
Bioorganic Chemistry , 2015
114.
Benzoxaboroles as Efficient Inhibitors of the β-Carbonic Anhydrases from Pathogenic Fungi: Activity and Modeling Study
Nocentini A., Cadoni R., del Prete S., Capasso C., Dumy P., Gratteri P., Supuran C.T., Winum J.
ACS Medicinal Chemistry Letters , 2017
115.
Benzoxaborole as a new chemotype for carbonic anhydrase inhibition
Alterio V., Cadoni R., Esposito D., Vullo D., Fiore A.D., Monti S.M., Caporale A., Ruvo M., Sechi M., Dumy P., Supuran C.T., Simone G.D., Winum J.
Chemical Communications , 2016
116.
Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase
Hu Q., Liu R., Fang Z., Zhang J., Ding Y., Tan M., Wang M., Pan W., Zhou H., Wang E.
Scientific Reports , 2013
117.
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock F.L., Mao W., Yaremchuk A., Tukalo M., Crépin T., Zhou H., Zhang Y., Hernandez V., Akama T., Baker S.J., Plattner J.J., Shapiro L., Martinis S.A., Benkovic S.J., Cusack S., et. al.
Science , 2007
118.
Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents
Hurdle J.G., O'Neill A.J., Chopra I.
Antimicrobial Agents and Chemotherapy , 2005
119.
rcr_90_4_451bib119
Al-Zoubi
2017
120.
The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis
Korkegian A., O'Malley T., Xia Y., Zhou Y., Carter D.S., Sunde B., Flint L., Thompson D., Ioerger T.R., Sacchettini J., Alley M.R., Parish T.
Tuberculosis , 2018
121.
rcr_90_4_451bib121
Patel
Antimicrob. Agents Chemother. , 2017
122.
Synthesis and evaluation of functionalized benzoboroxoles as potential anti-tuberculosis agents
Alam M.A., Arora K., Gurrapu S., Jonnalagadda S.K., Nelson G.L., Kiprof P., Jonnalagadda S.C., Mereddy V.R.
Tetrahedron , 2016
123.
Antibiotics in late clinical development
Fernandes P., Martens E.
Biochemical Pharmacology , 2017
124.
Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin
Lapa G.B., Mirchink E.P., Isakova E.B., Preobrazhenskaya M.N.
Journal of Enzyme Inhibition and Medicinal Chemistry , 2017
125.
rcr_90_4_451bib125
Printsevskaya
Antibiot. Khimioterap. , 2018
126.
Synthesis and evaluation of biological activity of benzoxaborole derivatives of azithromycin
Tevyashova A.N., Korolev A.M., Mirchink E.P., Isakova E.B., Osterman I.A.
Journal of Antibiotics , 2018
127.
Hospital-Acquired Infections Due to Gram-Negative Bacteria
Peleg A.Y., Hooper D.C.
New England Journal of Medicine , 2010
128.
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé É., Woerther P., Barbier F.
Annals of Intensive Care , 2015
129.
Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria
Hernandez V., Crépin T., Palencia A., Cusack S., Akama T., Baker S.J., Bu W., Feng L., Freund Y.R., Liu L., Meewan M., Mohan M., Mao W., Rock F.L., Sexton H., et. al.
Antimicrobial Agents and Chemotherapy , 2013
130.
Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections
O'Dwyer K., Spivak A.T., Ingraham K., Min S., Holmes D.J., Jakielaszek C., Rittenhouse S., Kwan A.L., Livi G.P., Sathe G., Thomas E., Van Horn S., Miller L.A., Twynholm M., Tomayko J., et. al.
Antimicrobial Agents and Chemotherapy , 2015
131.
In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens
Purnapatre K.P., Rao M., Pandya M., Khanna A., Chaira T., Bambal R., Upadhyay D.J., Masuda N.
Antimicrobial Agents and Chemotherapy , 2018
132.
DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa
Kumar M., Rao M., Purnapatre K.P., Barman T.K., Joshi V., Kashyap A., Chaira T., Bambal R.B., Pandya M., Khodor S.A., Upadhyay D.J., Masuda N.
Antimicrobial Agents and Chemotherapy , 2019
133.
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT)
Akama T., Zhang Y., Freund Y.R., Berry P., Lee J., Easom E.E., Jacobs R.T., Plattner J.J., Witty M.J., Peter R., Rowan T.G., Gillingwater K., Brun R., Nare B., Mercer L., et. al.
Bioorganic and Medicinal Chemistry Letters , 2018
134.
Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome
Jones D.C., Foth B.J., Urbaniak M.D., Patterson S., Ong H.B., Berriman M., Fairlamb A.H.
PLoS Neglected Tropical Diseases , 2015
135.
rcr_90_4_451bib135
136.
Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei
Steketee P.C., Vincent I.M., Achcar F., Giordani F., Kim D., Creek D.J., Freund Y., Jacobs R., Rattigan K., Horn D., Field M.C., MacLeod A., Barrett M.P.
PLoS Neglected Tropical Diseases , 2018
137.
Clinical and veterinary trypanocidal benzoxaboroles target CPSF3
Wall R.J., Rico E., Lukac I., Zuccotto F., Elg S., Gilbert I.H., Freund Y., Alley M.R., Field M.C., Wyllie S., Horn D.
Proceedings of the National Academy of Sciences of the United States of America , 2018
138.
rcr_90_4_451bib138
Zhang
PLoS Pathogens , 2018
139.
The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing
Begolo D., Vincent I.M., Giordani F., Pöhner I., Witty M.J., Rowan T.G., Bengaly Z., Gillingwater K., Freund Y., Wade R.C., Barrett M.P., Clayton C.
PLoS Pathogens , 2018
140.
Bacterial, fungal and protozoan carbonic anhydrases as drug targets
Capasso C., Supuran C.T.
Expert Opinion on Therapeutic Targets , 2015
141.
Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets
Vermelho A.B., Capaci G.R., Rodrigues I.A., Cardoso V.S., Mazotto A.M., Supuran C.T.
Bioorganic and Medicinal Chemistry , 2017
143.
Carbonic anhydrases fromTrypanosoma cruziandLeishmania donovani chagasiare inhibited by benzoxaboroles
Nocentini A., Cadoni R., Dumy P., Supuran C.T., Winum J.
Journal of Enzyme Inhibition and Medicinal Chemistry , 2017
144.
A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue
Sonoiki E., Ng C.L., Lee M.C., Guo D., Zhang Y., Zhou Y., Alley M.R., Ahyong V., Sanz L.M., Lafuente-Monasterio M.J., Dong C., Schupp P.G., Gut J., Legac J., Cooper R.A., et. al.
Nature Communications , 2017
145.
Targeting Toxoplasma gondii CPSF 3 as a new approach to control toxoplasmosis
Palencia A., Bougdour A., Brenier‐Pinchart M., Touquet B., Bertini R., Sensi C., Gay G., Vollaire J., Josserand V., Easom E., Freund Y.R., Pelloux H., Rosenthal P.J., Cusack S., Hakimi M., et. al.
EMBO Molecular Medicine , 2017
146.
Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase
Sonoiki E., Palencia A., Guo D., Ahyong V., Dong C., Li X., Hernandez V.S., Zhang Y., Choi W., Gut J., Legac J., Cooper R., Alley M.R., Freund Y.R., DeRisi J., et. al.
Antimicrobial Agents and Chemotherapy , 2016
147.
Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase
Palencia A., Liu R., Lukarska M., Gut J., Bougdour A., Touquet B., Wang E., Li X., Alley M.R., Freund Y.R., Rosenthal P.J., Hakimi M., Cusack S.
Antimicrobial Agents and Chemotherapy , 2016
148.
Benzoxaborole Antimalarial Agents. Part 4. Discovery of Potent 6-(2-(Alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles
Zhang Y., Plattner J.J., Easom E.E., Jacobs R.T., Guo D., Sanders V., Freund Y.R., Campo B., Rosenthal P.J., Bu W., Gamo F., Sanz L.M., Ge M., Li L., Ding J., et. al.
Journal of Medicinal Chemistry , 2015
149.
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate
Zhang Y., Plattner J.J., Easom E.E., Jacobs R.T., Guo D., Freund Y.R., Berry P., Ciaravino V., Erve J.C., Rosenthal P.J., Campo B., Gamo F., Sanz L.M., Cao J.
Journal of Medicinal Chemistry , 2017
150.
rcr_90_4_451bib150
Sindhe
Am. J. Trop. Med. Hyg. , 2017
151.
Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles
Van Bocxlaer K., Gaukel E., Hauser D., Park S.H., Schock S., Yardley V., Randolph R., Plattner J.J., Merchant T., Croft S.L., Jacobs R.T., Wring S.A.
Antimicrobial Agents and Chemotherapy , 2018
152.
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
Van Bocxlaer K., Caridha D., Black C., Vesely B., Leed S., Sciotti R.J., Wijnant G., Yardley V., Braillard S., Mowbray C.E., Ioset J., Croft S.L.
International Journal for Parasitology: Drugs and Drug Resistance , 2019
153.
rcr_90_4_451bib153
154.
Leishmania donovani Parasites Are Inhibited by the Benzoxaborole AN2690 Targeting Leucyl-tRNA Synthetase
Manhas R., Tandon S., Sen S.S., Tiwari N., Munde M., Madhubala R.
Antimicrobial Agents and Chemotherapy , 2018
156.
Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target
Long T., Rojo-Arreola L., Shi D., El-Sakkary N., Jarnagin K., Rock F., Meewan M., Rascón A.A., Lin L., Cunningham K.A., Lemieux G.A., Podust L., Abagyan R., Ashrafi K., McKerrow J.H., et. al.
PLoS Neglected Tropical Diseases , 2017
157.
Discovery of an orally bioavailable isoxazoline benzoxaborole ( AN8030 ) as a long acting animal ectoparasiticide
Zhang Y., Plattner J.J., Easom E.E., Zhou Y., Akama T., Bu W., White W.H., Defauw J.M., Winkle J.R., Balko T.W., Guo S., Xue J., Cao J., Zou W.
Bioorganic and Medicinal Chemistry Letters , 2015
158.
Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide
Zhang Y., Plattner J.J., Easom E.E., Akama T., Zhou Y., White W.H., Defauw J.M., Winkle J.R., Balko T.W., Cao J., Ge Z., Yang J.
Bioorganic and Medicinal Chemistry Letters , 2016
159.
Wadood A., Riaz M., Jamal S.B., Shah M., Lodhi M.A.
Bioinformation , 2013
160.
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease
Li X., Zhang Y., Liu Y., Zhang S., Ding C.Z., Zhou Y., Plattner J.J., Baker S.J., Liu L., Bu W., Kazmierski W.M., Wright L.L., Smith G.K., Jarvest R.L., Duan M., et. al.
Bioorganic and Medicinal Chemistry Letters , 2010
161.
Design of N-Benzoxaborole Benzofuran GSK8175—Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor
Chong P.Y., Shotwell J.B., Miller J., Price D.J., Maynard A., Voitenleitner C., Mathis A., Williams S., Pouliot J.J., Creech K., Wang F., Fang J., Zhang H., Tai V.W., Turner E., et. al.
Journal of Medicinal Chemistry , 2019
162.
Convergent Synthesis of the NS5B Inhibitor GSK8175 Enabled by Transition Metal Catalysis
Arrington K., Barcan G.A., Calandra N.A., Erickson G.A., Li L., Liu L., Nilson M.G., Strambeanu I.I., VanGelder K.F., Woodard J.L., Xie S., Allen C.L., Kowalski J.A., Leitch D.C.
Journal of Organic Chemistry , 2018
163.
Synthesis and evaluation of functionalized aminobenzoboroxoles as potential anti -cancer agents
Suman P., Patel B.P., Kasibotla A.V., Solano L.N., Jonnalagadda S.C.
Journal of Organometallic Chemistry , 2015
164.
Chalcone–benzoxaborole hybrids as novel anticancer agents
Zhang J., Yang F., Qiao Z., Zhu M., Zhou H.
Bioorganic and Medicinal Chemistry Letters , 2016
165.
Antiproliferative and pro-apoptotic activities of 2′- and 4′-aminochalcones against tumor canine cells
Santos M.B., Pinhanelli V.C., Garcia M.A., Silva G., Baek S.J., França S.C., Fachin A.L., Marins M., Regasini L.O.
European Journal of Medicinal Chemistry , 2017
166.
rcr_90_4_451bib166
Stein Gold
J. Drugs Dermatol. , 2015
167.
rcr_90_4_451bib167
Murrell
J. Drugs Dermatol. , 2015
168.
rcr_90_4_451bib168
Jarnagin
J. Drugs Dermatol. , 2016
169.
Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes
Dong C., Virtucio C., Zemska O., Baltazar G., Zhou Y., Baia D., Jones-Iatauro S., Sexton H., Martin S., Dee J., Mak Y., Meewan M., Rock F., Akama T., Jarnagin K., et. al.
Journal of Pharmacology and Experimental Therapeutics , 2016
170.
A hit deconstruction approach for the discovery of fetal hemoglobin inducers
Benowitz A.B., Eberl H.C., Erickson-Miller C.L., Gilmartin A.G., Gore E.R., Montoute M.N., Wu Z.
Bioorganic and Medicinal Chemistry Letters , 2018
171.
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
Liu B., Trout R.E., Chu G., McGarry D., Jackson R.W., Hamrick J.C., Daigle D.M., Cusick S.M., Pozzi C., De Luca F., Benvenuti M., Mangani S., Docquier J., Weiss W.J., Pevear D.C., et. al.
Journal of Medicinal Chemistry , 2019
172.
Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
Krajnc A., Brem J., Hinchliffe P., Calvopiña K., Panduwawala T.D., Lang P.A., Kamps J.J., Tyrrell J.M., Widlake E., Saward B.G., Walsh T.R., Spencer J., Schofield C.J.
Journal of Medicinal Chemistry , 2019
174.
Broad Spectrum β-Lactamase Inhibition by a Thioether Substituted Bicyclic Boronate
Parkova A., Lucic A., Krajnc A., Brem J., Calvopiña K., Langley G.W., McDonough M.A., Trapencieris P., Schofield C.J.
ACS Infectious Diseases , 2019
175.
rcr_90_4_451bib175
177.
The effect of BACE1-AS on β-amyloid generation by regulating BACE1 mRNA expression
Li F., Wang Y., Yang H., Xu Y., Zhou X., Zhang X., Xie Z., Bi J.
BMC Molecular Biology , 2019
178.
Design, synthesis and evaluations of spiro‐fused benzoxaborin derivatives as novel boron‐containing compounds
Natsutani I., Iwata R., Yamai Y., Ishida K., Nagaoka Y., Sumiyoshi T.
Chemical Biology and Drug Design , 2019
179.
Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro
Davis M.C., Franzblau S.G., Martin A.R.
Bioorganic and Medicinal Chemistry Letters , 1998
180.
A facile synthesis of 2,4-diaza-1-borines from anilines
Lee G.T., Prasad K., Repič O.
Tetrahedron Letters , 2002
181.
Synthesis, Characterization, and Antifungal Activity of Boron-Containing Thiosemicarbazones
Hicks J., Kyle C., Vogels C., Wheaton S., Baerlocher F., Decken A., Westcott S.
Chemistry and Biodiversity , 2008
182.
Synthesis, Characterization, and Antibacterial Activity of Structurally Complex 2-Acylated 2,3,1-Benzodiazaborines and Related Compounds
Kanichar D., Roppiyakuda L., Kosmowska E., Faust M.A., Tran K.P., Chow F., Buglo E., Groziak M.P., Sarina E.A., Olmstead M.M., Silva I., Xu H.H.
Chemistry and Biodiversity , 2014
183.
Diazaborines as New Inhibitors of Human Neutrophil Elastase
António J.P., Gonçalves L.M., Guedes R.C., Moreira R., Gois P.M.
ACS Omega , 2018
184.
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogs
Grassberger M.A., Turnowsky F., Hildebrandt J.
Journal of Medicinal Chemistry , 1984
185.
Diazaborine Treatment of Yeast Cells Inhibits Maturation of the 60S Ribosomal Subunit
Pertschy B., Zisser G., Schein H., Köffel R., Rauch G., Grillitsch K., Morgenstern C., Durchschlag M., Högenauer G., Bergler H.
Molecular and Cellular Biology , 2004
186.
The Drug Diazaborine Blocks Ribosome Biogenesis by Inhibiting the AAA-ATPase Drg1
Loibl M., Klein I., Prattes M., Schmidt C., Kappel L., Zisser G., Gungl A., Krieger E., Pertschy B., Bergler H.
Journal of Biological Chemistry , 2014
187.
Crystallographic insights into the structure–activity relationships of diazaborine enoyl-ACP reductase inhibitors
Jordan C.A., Sandoval B.A., Serobyan M.V., Gilling D.H., Groziak M.P., Xu H.H., Vey J.L.
Acta Crystallographica Section F:Structural Biology Communications , 2015
188.
Discovery of a cofactor-independent inhibitor ofMycobacterium tuberculosisInhA
Xia Y., Zhou Y., Carter D.S., McNeil M.B., Choi W., Halladay J., Berry P.W., Mao W., Hernandez V., O'Malley T., Korkegian A., Sunde B., Flint L., Woolhiser L.K., Scherman M.S., et. al.
Life Science Alliance , 2018
189.
rcr_90_4_451bib189
190.
Synthesis, Characterisation, and Antifungal Activities of Novel Benzodiazaborines
Yang J., Johnson B.J., Letourneau A.A., Vogels C.M., Decken A., Baerlocher F.J., Westcott S.A.
Australian Journal of Chemistry , 2015
191.
Synthesis, reactivity, and antimicrobial properties of boron-containing 4-ethyl-3-thiosemicarbazide derivatives
Scott R.S., Veinot A.J., Stack D.L., Gormley P.T., Khuong B.N., Vogels C.M., Masuda J.D., Baerlocher F.J., MacCormack T.J., Westcott S.A.
Canadian Journal of Chemistry , 2018
192.
Fast Diazaborine Formation of Semicarbazide Enables Facile Labeling of Bacterial Pathogens
Bandyopadhyay A., Cambray S., Gao J.
Journal of the American Chemical Society , 2017
193.
Boron-Based Inhibitors of the NLRP3 Inflammasome
Baldwin A.G., Rivers-Auty J., Daniels M.J., White C.S., Schwalbe C.H., Schilling T., Hammadi H., Jaiyong P., Spencer N.G., England H., Luheshi N.M., Kadirvel M., Lawrence C.B., Rothwell N.J., Harte M.K., et. al.
Cell Chemical Biology , 2017
194.
Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
Baldwin A.G., Tapia V.S., Swanton T., White C.S., Beswick J.A., Brough D., Freeman S.
ChemMedChem , 2018
195.
Sterile inflammatory responses mediated by the NLRP3 inflammasome
Cassel S.L., Sutterwala F.S.
European Journal of Immunology , 2010
196.
Photophysical and Electrochemiluminescence of Coumarin‐Based Oxazaborines
Mikysek T., Nikolaou P., Kafexholli M., Šimůnek P., Váňa J., Marková A., Vala M., Valenti G.
ChemElectroChem , 2020
197.
A new bicyclic oxazaborines with a bridged nitrogen atom, their thermic rearrangement and fluorescence properties
Josefík F., Svobodová M., Bertolasi V., Šimůnek P., Macháček V., Almonasy N., Černošková E.
Journal of Organometallic Chemistry , 2012
198.
Electrochemical and Theoretical Study of a New Series of Bicyclic Oxazaborines
Mikysek T., Kvapilová H., Josefík F., Ludvík J.
Analytical Letters , 2015
199.
New Triazaborine Chromophores: Their Synthesis via Oxazaborines and Electrochemical and DFT Study of Their Fundamental Properties
Josefík F., Mikysek T., Svobodová M., Šimůnek P., Kvapilová H., Ludvík J.
Organometallics , 2014
200.
Boron delivery agents for neutron capture therapy of cancer
Barth R.F., Mi P., Yang W.
Cancer Communications , 2018
201.
rcr_90_4_451bib201
Barth
Appl. Radiat. Isot. , 2020
203.
rcr_90_4_451bib203
Grimes
2016
204.
rcr_90_4_451bib204
Hey-Hawkins
2018
205.
rcr_90_4_451bib205
Hosmane
2019
206.
B H activation of carboranes induced by late transition metals
Yu W., Cui P., Gao W., Jin G.
Coordination Chemistry Reviews , 2017
207.
Transition-Metal-Catalyzed Selective Cage B−H Functionalization of o -Carboranes
Quan Y., Qiu Z., Xie Z.
Chemistry - A European Journal , 2018
208.
Nonclassical Applications of closo-Carborane Anions: From Main Group Chemistry and Catalysis to Energy Storage.
Fisher S.P., Tomich A.W., Lovera S.O., Kleinsasser J.F., Guo J., Asay M.J., Nelson H.M., Lavallo V.
Chemical Reviews , 2019
210.
Transition metal-induced B–H functionalization of o-carborane
Zhang X., Yan H.
Coordination Chemistry Reviews , 2019
211.
Synthesis of Polyhedral Borane Cluster Fused Heterocycles via Transition Metal Catalyzed B-H Activation
Cao K., Zhang C., Xu T., Wu J., Wen X., Jiang W., Chen M., Yang J.
Molecules , 2020
212.
rcr_90_4_451bib212
Li
Chin. J. Inorg. Chem. , 2017
213.
Theoretical investigations of the Ir-catalyzed direct borylation of B(3,6)–H of o-carborane: the actual catalyst, mechanism, and origin of regioselectivity
Bai H., Xu H., Zhang H., Guo Y., Shan J., Wei D., Zhu Y., Zhang S., Zhang W.
Catalysis Science and Technology , 2018
214.
Copper catalyzed/mediated direct B–H alkenylation/alkynylation in carboranes
Chen Y., Au Y.K., Quan Y., Xie Z.
Science China Chemistry , 2018
215.
Catalytic Regioselective Cage B(8)–H Arylation of o-Carboranes via “Cage-Walking” Strategy
Lyu H., Zhang J., Yang J., Quan Y., Xie Z.
Journal of the American Chemical Society , 2019
217.
Synthesis of conjugates of polyhedral boron hydrides with nucleosides
Druzina A.A., Bregadze V.I., Mironov A.F., Semioshkin A.A.
Russian Chemical Reviews , 2016
218.
Reactions of closo-dodecaborate amines. Towards novel bis-(closo-dodecaborates) and closo-dodecaborate conjugates with lipids and non-natural nucleosides
Laskova J., Kozlova A., Białek-Pietras M., Studzińska M., Paradowska E., Bregadze V., Leśnikowski Z.J., Semioshkin A.
Journal of Organometallic Chemistry , 2016
219.
Tuning a modular system – synthesis and characterisation of a boron-rich s-triazine-based carboxylic acid and amine bearing a galactopyranosyl moiety
Kellert M., Hoppenz P., Lönnecke P., Worm D.J., Riedl B., Koebberling J., Beck-Sickinger A.G., Hey-Hawkins E.
Dalton Transactions , 2020
220.
Identification and stabilization of a highly selective gastrin‐releasing peptide receptor agonist
Hoppenz P., Els‐Heindl S., Beck‐Sickinger A.G.
Journal of Peptide Science , 2019
221.
Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status
Sancho V., Di Florio A., W. Moody T., T. Jensen R.
Current Drug Delivery , 2010
222.
A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy
Hoppenz P., Els-Heindl S., Kellert M., Kuhnert R., Saretz S., Lerchen H., Köbberling J., Riedl B., Hey-Hawkins E., Beck-Sickinger A.G.
Journal of Organic Chemistry , 2019
223.
Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy
Worm D.J., Hoppenz P., Els-Heindl S., Kellert M., Kuhnert R., Saretz S., Köbberling J., Riedl B., Hey-Hawkins E., Beck-Sickinger A.G.
Journal of Medicinal Chemistry , 2019
224.
Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
Worm D.J., Els‐Heindl S., Beck‐Sickinger A.G.
Peptide Science , 2020
225.
THE METHOD FOR OBTAINING A DERIVATIVE CLOSO-DECABORATE ANION WITH PENDANTE DTPA-GROUP
Matveev E.Y., Akimov S.S., Kubasov A.S., Retivov V.M., Zhizhin K.Y., Kuznetsov N.T.
Fine Chemical Technologies , 2019
226.
Discrete Nanomolecular Polyhedral Borane Scaffold Supporting Multiple Gadolinium(III) Complexes as a High Performance MRI Contrast Agent
Goswami L.N., Ma L., Chakravarty S., Cai Q., Jalisatgi S.S., Hawthorne M.F.
Inorganic Chemistry , 2012
227.
Application of Nitroimidazole–Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy
Li R., Zhang J., Guo J., Xu Y., Duan K., Zheng J., Wan H., Yuan Z., Chen H.
Molecular Pharmaceutics , 2019
228.
Study of the tissue distribution of potential boron neutron-capture therapy agents based on conjugates of chlorin e 6 aminoamide derivatives with boron nanoparticles
Volovetskiy A.B., Shilyagina N.Y., Dudenkova V.V., Pasynkova S.O., Ignatova A.A., Mironov A.F., Grin M.A., Bregadze V.I., Feofanov A.V., Balalaeva I.V., Maslennikova A.V.
Biophysics (Russian Federation) , 2016
229.
rcr_90_4_451bib229
Korolkov
Mater. Today Commun. , 2020
230.
Modification of Fe3O4 nanoparticles with carboranes
Tulebayeva D.Z., Kozlovskiy A.L., Korolkov I.V., Gorin Y.G., Kazantsev A.V., Abylgazina L., Shumskaya E.E., Kaniukov E.Y., Zdorovets M.V.
Materials Research Express , 2018
231.
Fe3O4 Nanoparticles for Complex Targeted Delivery and Boron Neutron Capture Therapy
Dukenbayev K., Korolkov I., Tishkevich D., Kozlovskiy A., Trukhanov S., Gorin Y., Shumskaya E., Kaniukov E., Vinnik D., Zdorovets M., Anisovich M., Trukhanov A., Tosi D., Molardi C.
Nanomaterials , 2019
232.
Boron-incorporating hemagglutinating virus of Japan envelope (HVJ-E) nanomaterial in boron neutron capture therapy
Yoneoka S., Nakagawa Y., Uto K., Sakura K., Tsukahara T., Ebara M.
Science and Technology of Advanced Materials , 2019
234.
rcr_90_4_451bib234
Cheng
Adv. Mater. , 2019
235.
Carborane Derivative Conjugated with Gold Nanoclusters for Targeted Cancer Cell Imaging
Wang J., Chen L., Ye J., Li Z., Jiang H., Yan H., Stogniy M.Y., Sivaev I.B., Bregadze V.I., Wang X.
Biomacromolecules , 2017
237.
A Highly Potent Antibacterial Agent Targeting Methicillin-Resistant Staphylococcus aureus Based on Cobalt Bis(1,2-Dicarbollide) Alkoxy Derivative
Zheng Y., Liu W., Chen Y., Jiang H., Yan H., Kosenko I., Chekulaeva L., Sivaev I., Bregadze V., Wang X.
Organometallics , 2017
238.
New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies.
Stockmann P., Gozzi M., Kuhnert R., Sárosi M.B., Hey-Hawkins E.
Chemical Society Reviews , 2019
239.
Intercalation of Benzoxaborolate Anions in Layered Double Hydroxides: Toward Hybrid Formulations for Benzoxaborole Drugs
Sene S., Bégu S., Gervais C., Renaudin G., Mesbah A., Smith M.E., Mutin P.H., van der Lee A., Nedelec J., Bonhomme C., Laurencin D.
Chemistry of Materials , 2015
240.
Formulation of benzoxaborole drugs in PLLA: from materials preparation to in vitro release kinetics and cellular assays
Sene S., McLane J., Schaub N., Bégu S., Hubert Mutin P., Ligon L., Gilbert R.J., Laurencin D.
Journal of Materials Chemistry B , 2016
241.
Boronic Acid for the Traceless Delivery of Proteins into Cells
Andersen K.A., Smith T.P., Lomax J.E., Raines R.T.
ACS Chemical Biology , 2015
242.
Synthesis of water-soluble anthracene-appended benzoxaboroles and evaluation of their cis-1,2-diol recognition properties
Kusano S., Konishi S., Yamada Y., Hayashida O.
Organic and Biomolecular Chemistry , 2018
243.
rcr_90_4_451bib243
Suzuki
Chemistry Select , 2016
244.
rcr_90_4_451bib244
Kurogochi
Chemistry Select , 2018
245.
HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES
Pekol T., Daniels J.S., Labutti J., Parsons I., Nix D., Baronas E., Hsieh F., Gan L., Miwa G.
Drug Metabolism and Disposition , 2005
246.
rcr_90_4_451bib246
Jinna
Des. Devel. Ther. , 2015